Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to -$609.0 million.

  • Novartis Ag's Capital Expenditures fell 913.98% to -$609.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.5 billion, marking a year-over-year decrease of 1332.36%. This contributed to the annual value of -$1.5 billion for FY2025, which is 1332.36% down from last year.
  • Latest data reveals that Novartis Ag reported Capital Expenditures of -$609.0 million as of Q4 2025, which was down 913.98% from -$354.0 million recorded in Q3 2025.
  • Novartis Ag's 5-year Capital Expenditures high stood at -$168.0 million for Q1 2023, and its period low was -$609.0 million during Q4 2025.
  • Moreover, its 5-year median value for Capital Expenditures was -$283.5 million (2022), whereas its average is -$319.6 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 3703.7% in 2022, then crashed by 3743.84% in 2024.
  • Quarter analysis of 5 years shows Novartis Ag's Capital Expenditures stood at -$460.0 million in 2021, then surged by 33.48% to -$306.0 million in 2022, then plummeted by 32.68% to -$406.0 million in 2023, then tumbled by 37.44% to -$558.0 million in 2024, then decreased by 9.14% to -$609.0 million in 2025.
  • Its Capital Expenditures was -$609.0 million in Q4 2025, compared to -$354.0 million in Q3 2025 and -$331.0 million in Q2 2025.